split-banner-image

PANACEA

Closed

IBCSG 45-13/BIG 4-13: PANACEA

BCT Study Chair:

Sherene Loi

PANACEA is a phase I/II clinical trial for women with HER2 positive breast cancer that has spread to other areas around the breast (locally advanced) or to other parts of the body (metastatic or advanced breast cancer). Two treatments are being tested in PANACEA, Trastuzumab and MK-3475. Although both treatments have been given individually to breast cancer patients, PANACEA is the first study that will assess the benefits and side-effects of using them together. The aim of the PANACEA clinical trial is to determine whether trastuzumab and MK-3475 can be given together and to evaluate the side effects, treatment tolerability and effectiveness of this treatment.

INTERNATIONAL

37

INTERNATIONAL

Total number of trial

participants internationally

AUSTRALIA & NEW ZEALAND

21

AUSTRALIA & NEW ZEALAND

Total number of trial participants

in Australia and New Zealand

INSTITUTIONS

2

INSTITUTIONS

Total number of participating institutions

in Australia and New Zealand

PANACEA PUBLICATIONS

2019

Improving the outcomes of checkpoint inhibitors in breast cancer.

Peoples GE. Lancet Oncology. 2019; 20(3):316-318 (epub 11/02/19 , http://dx.doi.org/10.1016/S1470-2045(19)30068-3), Editorial

Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b–2 trial.

Loi S, Giobbie-Hurder A, Gombos A, Bachelot T, Hui R, Curigliano G, Campone M, Biganzoli L, Bonnefoi H, Jerusalem G, Bartsch R, Rabaglio-Poretti M, Kammler R, Maibach R, Smyth MJ, Di Leo A, Colleoni M, Viale G, Regan MM, Andre F, for the International Breast Cancer Study Group and the Breast International Group. Lancet Oncology 2019; 20(3):371-382, (epub 11/02/2019), Journal

2017

Phase Ib/II study evaluating safety and efficacy of pembrolizumab and trastuzumab in patients with trastuzumab-resistant HER2-positive metastatic breast cancer: Results from the PANACEA (IBCSG 45-13/BIG 4-13/KEYNOTE-014) study.

Loi S, Giobbe-Hurder A, Gombos A, Bachelot T, Hui R, Curigliano G, Campone M, Biganzoli L, Bonnefoi H, Jerusalem G, Bartsch R, Rabaglio-Poretti M, Kammler R, Maibach R, Smyth MJ, Di Leo A, Colleoni M, Viale G, Regan MM, Andre F. SABCS 2017; GS2-06 (oral presentation), Comment

2015

PANACEA (IBCSG 45-13/BIG 4-13): A phase Ib/II trial evaluating the efficacy of pembrolizumab and trastuzumab in patients with trastuzumab-resistant, HER2-positive, metastatic breast cancer

Loi S, Andre F, Maibach R, Hui R, Bartsch R, Jerusalem G, Gombos A, Campone M, Bonnefoi H, Bachelot T, Curigliano G, Biganzoli L, Giobbie-Hurder A SABCS 2015 2015; OT3-01-05, Poster